Afferent Pharmaceuticals, a Palo Alto, CA-based company focused on developing compounds that treat chronic pain, closed a $23m Series A financing round.
The round was led by Third Rock Ventures and Pappas Ventures, with participation from Domain Associates and New Leaf Venture Partners.
The funds will be used to accelerate the development of P2X3 receptor targeted pain therapies. In conjunction with the financing, Afferent has exclusively licensed the P2X3 program from Basel, Switzerland-based Roche (SIX: RO, ROG; OTCQX: RHHBY), the company leader in research-focused healthcare.
Launched in December 2009, Afferent is led by Anthony P. Ford, Ph.D., chief scientific officer and a recognized expert in the P2X3 field.